Hoge Financial Services LLC Acquires 68 Shares of Eli Lilly and Company (NYSE:LLY)

Hoge Financial Services LLC raised its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 18.4% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 438 shares of the company’s stock after purchasing an additional 68 shares during the quarter. Hoge Financial Services LLC’s holdings in Eli Lilly and Company were worth $362,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. increased its stake in Eli Lilly and Company by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 74,248,997 shares of the company’s stock valued at $57,320,226,000 after purchasing an additional 475,530 shares in the last quarter. Geode Capital Management LLC increased its stake in Eli Lilly and Company by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 17,382,846 shares of the company’s stock valued at $13,389,651,000 after purchasing an additional 291,875 shares in the last quarter. GAMMA Investing LLC increased its stake in Eli Lilly and Company by 103,831.6% during the 1st quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company’s stock valued at $12,278,292,000 after purchasing an additional 14,852,076 shares in the last quarter. Wellington Management Group LLP increased its stake in Eli Lilly and Company by 19.0% during the 4th quarter. Wellington Management Group LLP now owns 12,625,925 shares of the company’s stock valued at $9,747,214,000 after purchasing an additional 2,012,129 shares in the last quarter. Finally, Norges Bank bought a new stake in Eli Lilly and Company during the 4th quarter valued at $8,407,908,000. Institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on LLY shares. Hsbc Global Res downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a report on Monday, April 28th. Morgan Stanley reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Erste Group Bank downgraded shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a report on Thursday, June 5th. Guggenheim reaffirmed a “buy” rating on shares of Eli Lilly and Company in a report on Friday, May 23rd. Finally, HSBC downgraded shares of Eli Lilly and Company from a “buy” rating to a “reduce” rating and cut their price objective for the stock from $1,150.00 to $700.00 in a report on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have issued a buy rating to the stock. According to MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $1,011.37.

Eli Lilly and Company Trading Down 2.0%

Shares of Eli Lilly and Company stock opened at $791.61 on Wednesday. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53. The stock’s 50-day simple moving average is $777.90 and its 200 day simple moving average is $801.70. The stock has a market capitalization of $750.24 billion, a P/E ratio of 64.41, a P/E/G ratio of 1.18 and a beta of 0.40. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The firm had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. During the same quarter in the prior year, the firm posted $2.58 earnings per share. The company’s revenue was up 45.2% on a year-over-year basis. As a group, research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Friday, May 16th were paid a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.76%. The ex-dividend date of this dividend was Friday, May 16th. Eli Lilly and Company’s dividend payout ratio is currently 48.82%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.